These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 28652705

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofán F, Torregrosa JV, Peri L, Ruiz Á, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.
    Ann Transplant; 2015 Nov 26; 20():707-13. PubMed ID: 26608590
    [Abstract] [Full Text] [Related]

  • 7. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May 26; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

  • 8. The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor-based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation.
    Zitta S, Schaffellner S, Gutschi J, Meinitzer A, Kniepeiss D, Artinger K, Reibnegger G, Rosenkranz AR, Wagner D.
    Transplantation; 2015 Jun 26; 99(6):1250-6. PubMed ID: 25606796
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2011 Feb 01; 13(1):49-69. PubMed ID: 21162600
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J, Bridson JM, Sharma A, Halawa A.
    Exp Clin Transplant; 2017 Jun 01; 15(3):241-252. PubMed ID: 27915965
    [Abstract] [Full Text] [Related]

  • 12. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Jun 01; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR.
    Clin J Am Soc Nephrol; 2017 Aug 07; 12(8):1321-1336. PubMed ID: 28576905
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Aug 07; 9():1217-24. PubMed ID: 25759566
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.